Daily Stock Analysis, GLD, GLAUKOS CORP, priceseries

GLAUKOS CORP. Daily Stock Analysis
Stock Information
Open
138.53
Close
138.76
High
139.00
Low
138.10
Previous Close
138.71
Daily Price Gain
0.05
YTD High
146.82
YTD High Date
Sep 4, 2019
YTD Low
119.54
YTD Low Date
May 2, 2019
YTD Price Change
17.43
YTD Gain
14.37%
52 Week High
146.82
52 Week High Date
Sep 4, 2019
52 Week Low
114.59
52 Week Low Date
Nov 28, 2018
52 Week Price Change
22.90
52 Week Gain
19.77%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 22. 2017
120.94
Jan 30. 2018
127.15
24 Trading Days
5.14%
Link
LONG
May 31. 2019
123.33
Jul 1. 2019
130.61
21 Trading Days
5.90%
Link
Company Information
Stock Symbol
GLD
Exchange
NYSE
Company URL
http://www.glaukos.com
Company Phone
949-367-9600
CEO
Thomas William Burns
Headquarters
California
Business Address
229 AVENIDA FABRICANTE, SAN CLEMENTE, CA 92672
Sector
Equity
Industry Category
Health Services
Industry Group
Medical Instruments & Supplies
CIK
0001192448
About

Description

Glaukos Corporation, an ophthalmic medical technology company, focuses on the development and commercialization of products and procedures designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry with the goal of achieving intraocular pressure reduction; iStent Supra suprachoroidal micro-bypass stent, which is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration. It markets its products through direct sales force in the United States and internationally, as well as through distribution partners in Europe, the Asia Pacific, and internationally. Glaukos Corporation was founded in 1998 and is headquartered in San Clemente, California.